Paladin Therapeutics

Paladin Pharma is a Canada-based specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative medicines for the Canadian market. Historically operated as an Endo business, Paladin marketed a portfolio of specialty and branded pharmaceutical products using an established medical, marketing, and sales organization in Canada. Publicly disclosed examples of Paladin-associated products and partnerships include XCOPRI for partial-onset seizures, Wynzora Cream for plaque psoriasis, and abaloparatide rights in Canada under a Radius agreement. In June 2025, Knight Therapeutics completed the acquisition of the Paladin business from Endo, making Paladin an acquired operating business within Knight’s Canadian platform. The business appears focused primarily on commercialization and lifecycle expansion of in-licensed assets rather than discovery R&D.